恩替卡韦联合复方鳖甲软肝片治疗慢性乙型肝炎患者的疗效  

Effect of entecavir combined with Fufangbiejiaruangan treatment in patients with chronic hepatitis B

作　　者：黄平[1] 杨高雄[1] 黄新[1] 林龙[1] 

机构地区：[1]廉江市人民医院感染内科,廉江市524400

出　　处：《中华实验和临床感染病杂志（电子版）》2017年第6期603-606,共4页Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition)

摘　　要：目的观察恩替卡韦联合复方鳖甲软肝片在慢性乙型肝炎患者中的临床治疗效果。方法选取2012年6月至2015年4月于本院肝病门诊诊治的慢性乙型肝炎患者160例,采用随机数字法分为对照组(80例)和观察组(80例)。对照组患者采用恩替卡韦治疗,观察组患者联合复方鳖甲软肝片治疗,比较两组患者的临床疗效。结果治疗后观察组患者丙氨酸氨基转移酶(ALT)[(31.2±19.4)U/L]、天门冬氨酸氨基转移酶(AST)[(34.9±21.5)U/L]及总胆红素(TBil)[(16.3±7.0)μmol/L]水平均低于对照组[ALT(47.8±32.1)U/L、AST(48.8±42.1)U/L及TBil(17.1±8.3)μmol/L](t=16.348、19.284、17.395,P=0.032、0.042、0.026),差异均具有统计学意义。治疗后观察组患者白蛋白(ALB)高于对照组,HBV DNA载量、血清HA、LN、PC-Ⅲ、Ⅳ-C水平均显著低于对照组(P均<0.05),差异均具有统计学意义。治疗48周后,观察组患者不良反应发生率(7.5%)显著低于对照组(20.0%)(χ~2=6.31、P=0.041)。结论慢性乙型肝炎患者在恩替卡韦治疗基础上联合复方鳖甲软肝片疗效较好。Objective To investigate the clinical therapeutic effect of entecavir combined with Fufangbiejiaruangan in patients with chronic hepatitis B （CHB）. Methods Total of 160 patients with CHB diagnosed and treated in our hospital from June 2012 to April 2015 were collected, and were divided into control group （80 cases） and observation group （80 cases） by random number method. The patients in control group were treated with entecavir, while the patients in observation group were treated with entecavir and Fufangbiejiaruangan tablet. The rates of clinical efficacy of the two groups were compared. Results After treatment, the levels ofALT, AST and total bilirubin （TBil） of patients in observation group [（31.2 ± 19.4） U/L, （34.9 ± 21.5） U/L and （16.3 ± 7.0） μmol/L] were significantly lower than those of patients in the control group [ （47.8 ± 32.1） U/L, （48.8 ± 42.1） U/L and （17.1 ± 8.3） μmol/L], with significant difference, respectively （t = 16.348, 19.284, 17.395; P = 0.032, 0.042, 0.026）. The level of ALB in patients in observation group [ （43.8 ± 4.5） g/L] was significantly higher than that of the control group; the levels of serum HA, LN, HBV DNA, PC-III and IV-C of patients in the observation group were significantly lower than those in the control group, with significant difference （all P 〈 0.05）. After 48 weeks of treatment, the incidence of adverse reactions in the observation group was 7.5%, significantly lower than that of the control group （P = 0.041, Z2 = 6.31）. Conclusions Patients with CHB treated with entecavir combined with Fufangbiejiaruangan could get better clinical efficacy.

关 键 词：恩替卡韦 复方鳖甲软肝片 慢性乙型肝炎 疗效 

分 类 号：R512.62[医药卫生—内科学]